Compare The Coca-Cola Co K (KO) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Medpace Holdings Inc — how do they compare? The Coca-Cola Co K trades at $88.11 (market cap $377.63B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: The Coca-Cola Co K is far larger — about 22.5× Medpace Holdings Inc's market cap, and The Coca-Cola Co K pays a 2.42% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Medpace Holdings Inc for 14 Days on average.
| KO | MEDP | |
|---|---|---|
Market Cap | $377.63B | $16.82B |
Volume | 14,894,568 | 223,093 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $630.19 |
52-Week Low | $66.37 | $393.42 |
Typical Hold Time | 154 Days | 14 Days |
Enterprise Value | $404.81B | $16.44B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $88.05, up 2.6% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $0.97 versus $0.92, maintaining a 61.89% gross margin and 28.56% net income margin. Recent institutional buying activity and positive analyst sentiment (60.42% buy ratings) support the stock's upward trajectory.
KO presents a compelling investment case with consistent earnings outperformance and a 64-year dividend growth streak. However, elevated valuation ratios (P/E 26.36, P/S 7.55) and regional demand divergence pose risks. The consensus price target of $95.75 suggests 8.7% upside potential from current levels, supported by strong cash flow generation and brand dominance.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
